SC 13G



United States

Securities and Exchange Commission

Washington, D.C. 20549



Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2


(Amendment No.     )*



4D Molecular Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)


(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)



The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




CUSIP No. 35104E100

   Schedule 13G    Page 1 of 4



  Names of Reporting Persons


  David Schaffer


  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐



  SEC Use Only



  Citizenship or Place of Organization


  United States

Number of



Owned by






  Sole Voting Power




  Shared Voting Power




  Sole Dispositive Power




  Shared Dispositive Power




  Aggregate Amount Beneficially Owned by Each Reporting Person




  Check if the Aggregate Amount in Row (9) Excludes Certain Shares


  Not Applicable


  Percent of Class Represented by Amount in Row 9




  Type of Reporting Person



CUSIP No. 35104E100

   Schedule 13G    Page 2 of 4


ITEM 1.       (a)     Name of Issuer:

4D Molecular Therapeutics, Inc. (the “Issuer”).



Address of Issuer’s Principal Executive Offices:

5858 Horton Street #455, Emeryville, California 94608.

ITEM 2.       (a)     Name of Person Filing:

This statement is filed on behalf of David Schaffer (the “Reporting Person”).



Address or Principal Business Office:

The business address of the Reporting Person is c/o 4D Molecular Therapeutics Inc. 5858 Horton Street #455, Emeryville, CA 94608.



Citizenship of each Reporting Person is:

The Reporting Person is a citizen of the United States.



Title of Class of Securities:

Common stock, par value $0.0001 per share (“Common Stock”).



CUSIP Number:




Not applicable.




The ownership information below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2020, based upon 26,493,726 shares of Common Stock outstanding as of December 15, 2020 based on the prospectus filed with the Securities and Exchange Commission on December 14, 2020.



Amount beneficially owned:

The Shaffer-Hinh Family Trust (the “Trust”) is the record holder of 2,000,000 shares of Common Stock. Mr. Shaffer is a co-trustee of the Trust and as a result, may be deemed to beneficially own the shares of Common Stock held of record by the Trust.

CUSIP No. 35104E100

   Schedule 13G    Page 3 of 4



Percent of class: 7.5%



Number of shares as to which the person has:



Sole power to vote or to direct the vote: 0


Shared power to vote or direct the vote: 2,000,000


Sole power to dispose or to direct the disposition of: 0


Shared power to dispose or to direct the disposition of: 2,000,000



Ownership of Five Percent or Less of a Class.

Not applicable.



Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.



Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.



Identification and Classification of Members of the Group.

Not applicable.



Notice of Dissolution of Group.

Not applicable.


ITEM 10.


Not applicable.

CUSIP No. 35104E100

   Schedule 13G    Page 4 of 4



After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2021


David Schaffer, Ph.D.

/s/ David Schaffer